Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Authors: Guidon Amanda C , Burton Leeann B , Chwalisz Bart K , Hillis James , Schaller Teilo H , Amato Anthony A , Betof Warner Allison , Brastianos Priscilla K , Cho Tracey A , Clardy Stacey L , Cohen Justine V , Dietrich Jorg , Dougan Michael , Doughty Christopher T , Dubey Divyanshu , Gelfand Jeffrey M , Guptill Jeffrey T , Johnson Douglas B , Juel Vern C , Kadish Robert , Kolb Noah , LeBoeuf Nicole R , Linnoila Jenny , Mammen Andrew L , Martinez-Lage Maria , Mooradian Meghan J , Naidoo Jarushka , Neilan Tomas G , Reardon David A , Rubin Krista M , Santomasso Bianca D , Sullivan Ryan J , Wang Nancy , Woodman Karin , Zubiri Leyre , Louv William C , Reynolds Kerry L 
Published: July 2021

Expanding the US Food and Drug Administration–approved indications for immune checkpoint inhibitors in patients with cancer has resulted in therapeutic success and immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence of 1%–12% and a high fatality rate relative to other irAEs. Lack of standardized disease definitions and accurate phenotyping leads to syndrome misclassification and impedes development of evidence-based treatments and translational research. The objective of this study was to develop consensus guidance for an approach to irAE-Ns including disease definitions and severity grading. A working group of four neurologists drafted irAE-N consensus guidance and definitions, which were reviewed by the multidisciplinary Neuro irAE Disease Definition Panel including oncologists and irAE experts. A modified Delphi consensus process was used, with two rounds of anonymous ratings by panelists and two meetings to discuss areas of controversy. Panelists rated content for usability, appropriateness and accuracy on 9-point scales in electronic surveys and provided free text comments. Aggregated survey responses were incorporated into revised definitions. Consensus was based on numeric ratings using the RAND/University of California Los Angeles (UCLA) Appropriateness Method with prespecified definitions. 27 panelists from 15 academic medical centers voted on a total of 53 rating scales (6 general guidance, 24 central and 18 peripheral nervous system disease definition components, 3 severity criteria and 2 clinical trial adjudication statements); of these, 77% (41/53) received first round consensus. After revisions, all items received second round consensus. Consensus definitions were achieved for seven core disorders: irMeningitis, irEncephalitis, irDemyelinating disease, irVasculitis, irNeuropathy, irNeuromuscular junction disorders and irMyopathy. For each disorder, six descriptors of diagnostic components are used: disease subtype, diagnostic certainty, severity, autoantibody association, exacerbation of pre-existing disease or de novo presentation, and presence or absence of concurrent irAE(s). These disease definitions standardize irAE-N classification. Diagnostic certainty is not always directly linked to certainty to treat as an irAE-N (ie, one might treat events in the probable or possible category). Given consensus on accuracy and usability from a representative panel group, we anticipate that the definitions will be used broadly across clinical and research settings.